This company specializes in producing medicinal polyethylene glycol (PEG) products, maintaining a long-standing cooperative relationship with PetroChina and listing in China in 2008. With an annual output of 20,000 tons, the company serves as a strategic partner to several major domestic pharma companies, exporting products to Europe, South America, Australia, East Asia and other regions; CEP certification is planned for May 2024 as Liaoning Oxiranpharm Inc. expands its focus to include APIs.

No hay comentarios disponibles.
Deja tu valoración & comentario